Introduction {#s1}
============

Human cytomegalovirus (HCMV), also called human herpes virus 5 (HHV5), is a beta herpesvirus that belongs to the Herpesviridae family ([@B21]; [@B22]; [@B61]). HCMV exhibits broad cellular tropism, capable of infecting most cell types and organs. As an opportunistic pathogen, HCMV is ubiquitous with a global infection distribution and causes more morbidity and mortality compared to any other herpes virus ([@B119]). Major HCMV transmission routes include saliva, sexual contact, placental transfer, breast feeding, blood transfusion, solid organ transplantation, and hematopoietic stem cell transplantation (HSCT; [@B84]; [@B43]). The incidence of infection and prevalence increases progressively with age, reaching over 70% prevalence by age 70 in developed countries. The seroprevalence rates can be more than 90% among lower socioeconomic groups, men who have sex with men, and in developing countries ([@B84]; [@B43]; [@B107]; [@B93]; [@B13]; [@B6]).

HCMV, with a double-stranded linear DNA genome ranging between 196 and 241 kbp (thousand base pairs), has the largest genome among the betaherpesviruses. The genome can encode over 160 gene products, a number much higher than other betaherpesviruses ([@B73]; [@B74]; [@B24]). Only a subset of the 160 genes have roles in herpesvirus core function such as DNA replication, DNA encapsulation, and virion maturation, whereas the majority are involved in viral persistence, latency, diverse cellular tropism, and host immune response modulation, indicating complex interactions throughout HCMV co-evolution with its human host ([@B111]). For example, HCMV encodes homologs of cellular chemokines, chemokine receptors, and cytokines, which might contribute to immune evasion of infected host cells ([@B68]).

The recognition of CMV as a medically important virus goes back to early 1930s when cytomegalic inclusion disease, a severe form of congenital CMV disease with an owl's eye appearance of inclusion bodies in cells from multiple organs of the infants, was observed. By 1970s, the pathogenic organ disease and HCMV link was well established, and HCMV-like viruses were isolated from other mammals. Due to the high social and medical cost of congenital CMV disease (i.e., sensorineural hearing loss and other severe neurological injury), vaccine development is a high public health priority ([@B89]; [@B3]). HCMV continued to draw increasing medical attention as an opportunistic infection in immunocompromised individuals receiving organ transplants and the elderly. Moreover, persistent HCMV infection has been demonstrated to accelerate immunosenescence also known as human immune aging ([@B56]; [@B55]; [@B86]; [@B120]; [@B85]). The onset of the HIV epidemic and the concomitant increase in AIDS-related CMV infections led to the development of several antiviral drugs ([@B89]; [@B36]; [@B58]; [@B106]; [@B116]). However, currently there is no protective vaccination, and viral resistance against available antiviral drugs necessitates continuing research and investment in better understanding of CMV pathogenesis ([@B88]; [@B98]; [@B42]; [@B36]; [@B90]).

Most reviews in CMV literature focus on the viral and immune response aspects of the pathogenesis. However, host genetics of viral infection and pathogenesis can identify biological pathways that may lead to novel therapeutics. This review takes a different approach and aims to cover the current cumulative state of the knowledge in the host genetics of CMV pathogenesis in different risk groups. Different phenotypic outcomes of HCMV susceptibility are presented in the following sections. The details of genetic associations such as cohorts, odds ratios, P-values, and sample size are presented in [**Table 1**](#T1){ref-type="table"}. A summary figure of interactions between host genes and HCMV in different phenotypic outcomes based on literature reports is presented in [**Figure 1**](#f1){ref-type="fig"}.

###### 

Loci reported to be involved in HCMV and related disease susceptibility.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phenotype                                   Gene                     Variant/genotype                   Location                             Sample size                                               Model                                          Effect                                                                                P-value         Population                                                                       Study group                                                                              Ref.
  ------------------------------------------- ------------------------ ---------------------------------- ------------------------------------ --------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -----------
  **Humoral immunity**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                              IGHG1                    GM 3                               Exon                                 131                                                       Recessive                                      Reduced anti-HCMV Glycoprotein B Immunoglobulin G (IgG) Antibody level                0.01            USA/Europeans                                                                    Upper Midwest Health Study                                                               ([@B80])

                                              IGHG1                    GM 5                               Exon                                 131                                                       Recessive                                      Reduced anti-HCMV Glycoprotein B Immunoglobulin G (IgG) Antibody level                0.01            USA/Europeans                                                                    Upper Midwest Health Study                                                               ([@B80])

                                              AGBL1                    rs2011905\                         Intron                               2442                                                      Allelic                                        Increased anti-CMV IgG titer                                                          1.9 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       -C Allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CD53                     rs2885805\                         Intron                               2442                                                      Allelic                                        Decreased anti-CMV IgG titer                                                          4.6 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              EFCAB4B                  rs4766152\                         Intron                               2442                                                      Allelic                                        Decreased anti-CMV IgG titer                                                          5.1 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              FREM2                    rs9594293\                         Intron                               2442                                                      Allelic                                        Decreased anti-CMV IgG titer                                                          6.8 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              MCPH1                    rs1707715\                         Intron                               2442                                                      Allelic                                        Increased anti-CMV IgG titer                                                          7.8 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       - G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                              TTC7B                    rs1779382\                         Intron                               2442                                                      Allelic                                        Increased anti-CMV IgG titer                                                          9.1 x 10^−6^    CVD-Finns                                                                        24--39 year old participants (GWAS)                                                      ([@B59])
                                                                       - A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                              LOC728667 or LINC00596   rs1288981\                         Between genes                        1300                                                      Allelic                                        Decreased IgG antibody response against HCMV                                          8.2 x 10^−7^    Mexican Americans in the San Antonio Family Study                                16--94 year old participants (GWAS)                                                      ([@B96])
                                                                       - T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Cancer susceptibility**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                              IGHG1                    GM 3                               --                                   253 (120 case, 133 control)                               Recessive                                      Increased risk of Glioma                                                              0.04            Portugal/European                                                                Patients with glioma                                                                     ([@B79])

                                              IGHG1                    GM 3/\                             --                                   253 (120 case, 133 control)                               Genotype                                       Increased risk of Glioma                                                              0.02            Portugal/European                                                                Patients with glioma                                                                     ([@B79])
                                                                       GM 17                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                              IGHG1                    GM 3                               --                                   258 case--control pair                                    Additive                                       Increased breast cancer risk                                                          0.01            Brazil/Europeans                                                                 Patients with invasive breast cancer                                                     ([@B77])

                                              IGHG1                    GM 3                               --                                   251                                                       Additive and Recessive                         Reduced anti-HCMV Glycoprotein B Immunoglobulin G (IgG) Antibody level                0.01--0.03      Brazil/Europeans                                                                 Breast cancer free controls                                                              ([@B81])

  **HCMV disease in transplantation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  ***Solid organ transplantation***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              TLR2                     R753Q\                             Exon                                 737 (92 cases, 645 controls)                              Recessive                                      Increased risk of CMV disease after liver transplantation                             0.003           USA/Europeans                                                                    Patients who received liver transplantation at the Mayo Clinic in Rochester, Minnesota   ([@B49])
                                                                       (rs5743708, 2258 G \> A)                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                              TLR2                     R753Q\                             Exon                                 92                                                        Recessive                                      Increased HCMV viral load and risk of CMV disease after liver transplantation         0.003--0.04     USA/Europeans                                                                    Patients who received liver transplantation at the Mayo Clinic in Rochester, Minnesota   ([@B52])
                                                                       (rs5743708, 2258 G \> A)                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                              TLR4                     D299G\                             Exon                                 245                                                       Presence of any of the variants                Increased risk of primary HCMV infection and disease                                  0.02            Spain                                                                            Patients who received kidney or kidney-pancreas transplantation                          ([@B14])
                                                                       (rs4986790) or T399I (rs498679)                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                              TLR9                     rs5743836 -- TT genotype           Upstream                             315                                                       Recessive                                      Lower incidence of HCMV infection                                                     0.035           Spain                                                                            Patients received kidney transplantation in the OPERA study                              ([@B30])

                                              DC-SIGN                  rs735240 -- GG genotype            Upstream                             315                                                       Recessive                                      Higher incidence of HCMV infection                                                    0.008           Spain                                                                            Patients received kidney transplantation in the OPERA study                              ([@B30])

                                              MBL2                     Biochemical deficiency/Null        --                                   16                                                        Recessive                                      Increased risk of HCMV infection                                                      0.005           Univ. Hospital, Lausanne, CH                                                     Patients who received kidney transplantation                                             ([@B66])

                                              PDCD1/\                  rs11568821\                        Intron                               469                                                       Recessive                                      Increased risk of HCMV infection                                                      0.01            Univ. Hospital, Tours, France                                                    Patients who received kidney transplantation                                             ([@B45])
                                              PD-1                     - G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                              PDCD1/\                  rs11568821\                        Intron                               1119                                                      Dominant                                       Improved kidney graft survival recipients receiving grafts from CMV-positive donors   0.002           Univ. Hospital, Tours, France                                                    Patients who received kidney transplantation                                             ([@B32])
                                              PD-1                     -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              PDCD1/\                  rs11568821\                        Intron                               181                                                       Dominant                                       Improved lung graft survival recipients receiving grafts from CMV-positive donors     0.006           University Hospital of Tours, France                                             Patients who received lung transplantation                                               ([@B32])
                                              PD-1                     -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IFNG                     +874T/A\                           Intron                               170                                                       Genotypic                                      High level of viremia and HCMV disease                                                0.001           USA/Europeans                                                                    Patients who received lung transplantation                                               ([@B70])
                                                                       (rs2430561)\                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                       -TT genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              IFNG                     +874T/A\                           247                                  Genotypic                                                 Increased risk of HCMV infection and disease   0.01                                                                                  USA/Hispanics   Patients who received kidney transplantation                                     ([@B117])                                                                                
                                                                       (rs2430561)\                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                       -AA genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              IFNL3/\                  rs8099917\                         5' Upstream region                   38 (17 with CMV replication, 21 no CMV replication)       Dominant                                       Reduced HCMV replication                                                              0.04            University of Alberta, Canada                                                    Patients who received solid organ transplantation                                        ([@B26])
                                              IFNL4                    -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IFNL3/\                  rs368234815\                       CpG region, 5' Upstream              840                                                       Recessive                                      Increased risk of HCMV replication and disease                                        0.05            Europeans/Swiss Transplant Cohort Study                                          Patients who received solid organ transplantation                                        ([@B67])
                                              IFNL4                    -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IFNL3/\                  rs12979860 -- T allele             Intro                                315                                                       Allelic                                        Lower incidence of HCMV infection                                                     0.03            Spain                                                                            Patients received kidney transplantation in the OPERA study                              ([@B30])
                                              IFNL4/IL28B                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                              IL-10                    -1082A/G\                          5' Upstream                          408                                                       Genotypic                                      Reduced incidence of HCMV infection                                                   0.03            Finland                                                                          Patients who received kidney transplantation                                             ([@B1])
                                                                       -AA genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              IL-12B                   rs3212227\                         3′-untransla-ted region              469                                                       Allelic                                        Increased risk of HCMV infection                                                      0.04            University Hospital of Tours, France                                             Patients who received kidney transplantation                                             ([@B44])
                                                                       -C allele (IL-12p40)                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                              MICA                     rs2596538                          5' Upstream region                   181                                                       Allelic                                        Protective against HCMV infection and disease                                         0.001           University Hospital Essen, Germany                                               Patients who received kidney transplantation                                             ([@B95])

  ***Hematopoietic transplantation***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                              IFNL3/\                  rs12979860\                        Intron                               151                                                       Genotypic                                      Protective against HCMV infection                                                     0.04            University Clinic Hospital of Valencia, Spain                                    Patients who received allogeneic stem cell transplantation                               ([@B12])
                                              IFNL4                    -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IFNL3/\                  rs12979860\                        Intron                               142                                                       Recessive                                      Protective against HCMV infection                                                     0.05            University Clinic Hospital of Valencia, Spain                                    Patients who received allogeneic stem cell transplantation                               ([@B19])
                                              IFNL4                    -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IFNL3/\                  rs12979860\                        Intron; Exon                         99                                                        Compound Genotypic                             Increased risk of HCMV activation                                                     \< 0.05         Italian cohorts                                                                  Patients who received allogeneic stem cell transplantation                               ([@B2])
                                              IFNL4                    -T allele; rs368234815-ΔG allele                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                              IL-10                    rs1800893\                         5' Upstream                          154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.009           Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10                    rs1800896\                         5' Upstream                          154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.001           Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10                    rs1878672\                         Intron                               154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.003           Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10                    rs3024492\                         Intron                               154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.04            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-7                     rs6897932\                         Exon                                 460                                                       Genotypic                                      Increased risk of HCMV infection                                                      0.007           Copenhagen University, Denmark                                                   Patients who received allogeneic stem cell transplantation                               ([@B51])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCL2 (MCP1)              rs1024611\                         5' Upstream                          154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV reactivation                                                   0.03            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCL2 (MCP1)              rs13900\                           Exon                                 154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV reactivation                                                   0.02            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCR5                     rs17141079\                        Intron                               154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.02            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCR5                     rs1800023\                         5' Upstream                          154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.01            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCR5                     rs1800023\                         5' Upstream                          102                                                       Additive, Recessive                            Increased CMV DNAemia and DNA peak                                                    0.02, 0.05      Spanish cohort                                                                   Patients who received allogeneic stem cell transplantation                               ([@B18])
                                                                       -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCR5                     rs2734648\                         5' Upstream                          154 (83 HCMV activation, 71 control)                      Additive                                       Increased risk of HCMV disease                                                        0.01            Multinational/Europeans                                                          Patients who received allogeneic stem cell transplantation                               ([@B63])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CD209\                   rs2287886\                         5' Upstream                          194 (70 HCMV reactivation, 59 HCMV disease, 65 control)   Allelic                                        Increased risk of development of HCMV reactivation and disease                        0.003           Germany/Europeans                                                                Patients who received allogeneic stem cell transplantation                               ([@B69])
                                              (DC-SIGN)                -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CD209\                   rs735240\                          5' Upstream                          194 (70 HCMV reactivation, 59 HCMV disease, 65 control)   Allelic                                        Increased risk of development of HCMV reactivation and disease                        0.01            Germany/Europeans                                                                Patients who received allogeneic stem cell transplantation                               ([@B69])
                                              (DC-SIGN)                -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              SDC2                     rs1042381\                         Exon                                 194 (70 HCMV reactivation, 59 HCMV disease, 65 control)   Allelic                                        Increased risk of development of HCMV reactivation and disease                        0.04            Germany/Europeans                                                                Patients who received allogeneic stem cell transplantation                               ([@B69])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              KIR2DS4                  KIR1D+ (deletion) haplotype        --                                   165                                                       Recessive                                      Increased risk of HCMV reactivation                                                   0.002           Chinese cohort                                                                   Patients with hematopoietic stem cell transplantation                                    ([@B122])

                                              STAT4                    Rs7574865\                         Intron                               161                                                       Recessive                                      Increased risk of HCMV infection                                                      0.01            Seoul National University, Korea                                                 Patients with hematopoietic stem cell transplantation                                    ([@B123])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              FOXP3                    Rs3761548\                         Intron                               171                                                       Recessive                                      Increased risk of HCMV infection                                                      0.01            Seoul National University, Korea                                                 Patients with hematopoietic stem cell transplantation                                    ([@B87])
                                                                       -C allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **HCMV disease in HIV infection**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              IL-10                    rs3024496\                         3' UTR                               534 (110 cases, 424 controls)                             Dominant                                       Susceptible to CMV-Retinitis                                                          0.05            USA/African Americans                                                            Patients with AIDS                                                                       ([@B103])
                                                                       -C Allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10                    rs3024500\                         3' UTR                               534 (110 cases, 424 controls)                             Dominant                                       Susceptible to CMV-Retinitis                                                          0.02            USA/African Americans                                                            Patients with AIDS                                                                       ([@B103])
                                                                       -C Allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10R1 (IL10RA)         rs2228055\                         Exon                                 750 (200 cases, 550 controls)                             Haplotypic                                     Susceptible to CMV-Retinitis                                                          0.04            USA/Europeans                                                                    Patients with AIDS                                                                       ([@B103])
                                                                       -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL-10R1 (IL10RA)         rs2229114\                         Exon                                 750 (200 cases, 550 controls)                             Allelic                                        Protective against CMV-Retinitis                                                      0.03            USA/Europeans                                                                    Patients with AIDS                                                                       ([@B103])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              CCR5                     rs1799988                          5' UTR, CCR5 P1 Promoter Haplotype   117                                                       Haplotypic                                     Increased risk of CMV-Retinitis progression                                           0.007           USA/African Americans                                                            Patients with AIDS                                                                       ([@B104])

                                              CCR5                     rs1799988                          5' UTR, CCR5 P1 Promoter Haplotype   203                                                       Haplotypic                                     Increased risk of mortality in patients with CMV-Retinitis                            0.05            USA/African Americans                                                            Patients with AIDS                                                                       ([@B104])

                                              CXCL12 (SDF1)            rs1801157\                         3′-untranslat-ed region              117                                                       Dominant                                       Increased risk of CMV-Retinitis progression                                           0.008           USA/African Americans                                                            Patients with AIDS                                                                       ([@B104])
                                                                       -A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              TNF                      4-1-G-2-2-1                        5' Upstream                          222 (52 CMV-retinitis, 170 control)                       Haplotypic                                     Susceptible to CMV-Retinitis                                                          0.03            Brazilian cohort (mixed race)                                                    Patients with AIDS                                                                       ([@B23])

                                              TNF                      TNFc1                              5' Upstream                          222 (52 CMV-retinitis, 170 control)                       Allelic                                        Protective against CMV-Retinitis                                                      0.04            Brazilian cohort (mixed race)                                                    Patients with AIDS                                                                       ([@B23])

                                              IFNL3/\                  rs368234815\                       CpG region, 5' Upstream              1134                                                      Recessive                                      Increased risk of CMV-retinitis                                                       0.007           Europeans/Swiss HIV Cohort Study                                                 Patients with HIV infection                                                              ([@B7])
                                              IFNL4                    -G allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **HCMV disease in vertical transmission**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                              TLR2                     rs1898830\                         Intron                               170 (87 case, 83 control)                                 Genotypic                                      decreased risk of congenital HCMV infection                                           0.03            Japanese cohort                                                                  Children with congenital HCMV infection                                                  ([@B114])
                                                                       -AG genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              TLR2                     rs1898830\                         Intron                               83 (33 case, 50 control)                                  Recessive                                      Protection against HCMV transmission                                                  0.008           Israeli cohort                                                                   Pregnant women with HCMV infection                                                       ([@B27])
                                                                       -GG genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              TLR2                     rs3804100\                         Exon                                 170 (87 case, 83 control)                                 Genotypic                                      Increased risk of congenital HCMV infection                                           0.01            Japanese cohort                                                                  Children with congenital HCMV infection                                                  ([@B114])
                                                                       (1350 T \> C)\                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                       -CC genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              TLR2                     Arg677Trp\                         Exon                                 229 (151 case, 78 control)                                Allelic                                        Reduced risk of infection only in adults                                              \< 0.001        Polish cohort                                                                    HCMV-infected children and adults                                                        ([@B46])
                                                                       (rs121917864, 2029 C \> T)                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                              TLR4                     D299G\                             Exon                                 229 (151 case, 78 control)                                Allelic                                        Reduced risk of infection only in adults                                              0.02            Polish cohort                                                                    HCMV-infected children and adults                                                        ([@B46])
                                                                       (rs4986790)                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                              TLR2                     R753Q\                             Exon                                 51 (20 case, 30 control)                                  Genotypic                                      increased risk of congenital HCMV infection                                           0.02            Polish cohort                                                                    HCMV-infected fetuses and neonates                                                       ([@B124])
                                                                       (rs5743708, 2258 G \> A)                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                              TLR9                     rs352140\                          Exon (synonymous change)             131 (66 case, 65 control)                                 Dominant                                       Reduced risk of HCMV infection in pregnant women                                      0.03            Polish cohort                                                                    HCMV-infected pregnant women                                                             ([@B125])
                                                                       (2848 G \> A)\                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                       - A allele                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                              TLR9                     rs352140\                          Exon (synonymous change)             142 (72 case, 70 control)                                 Genotypic                                      Increased risk of HCMV infection in infants                                           0.02            Polish cohort                                                                    Congenitally HCMV-infected infants                                                       ([@B83])
                                                                       (2848 G \> A)\                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                       -TC genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                              TLR9                     Rs187084\                          Upstream\                            142 (72 case, 70 control)                                 Dominant                                       Increased risk of HCMV infection in infants                                           0.02            Polish cohort                                                                    Congenitally HCMV-infected infants                                                       ([@B83])
                                                                       (-1486 T \> C)\                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                       -C allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL1A                     -889 C \> T                        5' Upstream                          51 (20 case, 31 control)                                  Allelic                                        increased risk of congenital HCMV infection and onset of related symptoms             \< 0.0001       Polish Mother's Memorial Hospital, Poland                                        Fetuses and Neonates with HCMV infection                                                 ([@B126])

                                              IL1A                     -889 C \> T                        5' Upstream                          129 (65 case, 64 control)                                 Recessive                                      Decreased risk of HCMV infection                                                      0.05            Polish Mother's Memorial Hospital, Poland                                        Pregnant women                                                                           ([@B127])

                                              IL1B                     rs1143634\                         Exon                                 51 (20 case, 31 control)                                  Allelic                                        increased risk of congenital HCMV infection and onset of related symptoms             \< 0.0001       Polish Mother's Memorial Hospital, Poland                                        Fetuses and Neonates with HCMV infection                                                 ([@B126])
                                                                       (+3954 C \> T)\                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL1B                     rs16944\                           5' Upstream                          470 (72 case, 398 control)                                Genotypic                                      increased risk of intrauterine HCMV infection                                         0.03            Infants enrolled at the Children's Memorial Health Institute in Warsaw, Poland   Infants with HCMV infection                                                              ([@B50])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              IL6                      -174 G \> C                        5' Upstream                          129 (65 case, 64 control)                                 Recessive                                      Decreased risk of HCMV infection in their offspring                                   0.02            Polish Mother's Memorial Hospital, Poland                                        Pregnant women                                                                           ([@B127])

                                              CCL2 (MCP1)              rs13900\                           Exon                                 470 (72 case, 398 control)                                Genotypic                                      increased risk of hearing loss at birth                                               0.03            Infants enrolled at the Children's Memorial Health Institute in Warsaw, Poland   Infants with HCMV infection                                                              ([@B50])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                              TNF                      rs1799964\                         5' Upstream                          470 (72 case, 398 control)                                Genotypic                                      increased risk of intrauterine HCMV infection                                         0.03            Infants enrolled at the Children's Memorial Health Institute in Warsaw, Poland   Infants with HCMV infection                                                              ([@B50])
                                                                       -T allele                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All values and information are based on the cited paper. Whenever case--control status or disease-specific divisions of patients were available, they are reported under the sample size column.

IGHG1: Immunoglobulin GM γ chain marker.

CVD-Finns: Cardiovascular risks in young Finns study.

![Human genes involved in response to HCMV and related diseases. Summary figure representing the interaction between host genes and HCMV in different phenotypic outcomes based on literature reports as listed and cited in [**Table 1**](#T1){ref-type="table"}. **(A)** Genes modulating humoral immunity response against HCMV. **(B)** Innate and adaptive immune response modulating genes unique to and shared between susceptibility to HCMV disease in transplantation, HIV infection, and vertical transmission categories. The grouping of genes among the phenotypic outcomes is deduced based on association results and related literature detailed in [**Table 1**](#T1){ref-type="table"}. "Vertical transmission" category is based on studies of transmission of HMCV from mother to fetus or newborn. "HCMV disease in transplantation" category includes results from solid organ and stem cell transplantation studies. "HCMV disease in HIV infection" category includes results from HIV-infected patients.](fgene-10-00616-g001){#f1}

Host Genetics of Humoral Immunity to HCMV {#s2}
=========================================

HCMV immune human sera contain neutralizing antibodies against principal CMV envelope proteins (such as gB), tegument phosphoprotein pp150 (UL32), and nonstructural DNA binding phosphoprotein pp52 (UL44) ([@B60]). Humoral immunity to CMV can be protective against blood-borne spread of virus, transplacental transmission, and CMV acquisition and disease ([@B48]; [@B91]; [@B99]; [@B31]; [@B97]). There is differential response to CMV exposure, and not everyone exposed to HCMV develops a CMV-related disease, suggesting a possible role for host genetic variation in antibody response to HCMV.

Immunoglobulins, also known as antibodies, constitute a critical part of the humoral immune response by specifically recognizing and binding to particular antigens. Immunoglobulin G is the most common type of antibody in circulation. Variation in genes that code for immunoglobulin (Ig) GM (gamma marker) creates several alleles (also referred as allotypes), (i.e., GM 3 and GM 17) with different binding affinities to antigens such as HCMV glycoprotein B (gB). The effect of genetic variation in humoral immunity on susceptibility to HCMV disease has been suggested by the studies that focus on association between immunoglobulin (Ig) GM allotype variation and HCMV antibody response. Pandey et al. reported a significant effect of immunoglobulin GM genotypes on antibody responsiveness to HCMV glycoprotein B (gB) ([@B78]). The study showed significant differences in antibody response to HCMV between GM 3 and GM 17 alleles. HCMV codes for a Fc gamma receptor (FcgR)-like protein (coded by the HCMV *RL13* gene) that can bind to the anti-HCMV IgG antibody, thus reducing the number of free anti-HCMV antibodies in circulation, and giving survival advantage to the virus. The GM 3 allele has higher affinity to HCMV FcgR-like protein (through bipolar bridging) compared to the GM 17 allele, leaving lower concentration of free anti-HCMV gB antibodies circulating in the system. They also drew attention to B-cell-mediated antigen processing/presentation pathway as an alternative mechanism underlying GM allotypes' differential responsiveness to HCMV gB. One of the strategies that HCMV has evolved for evading host immunosurveillance involves generating proteins with similar functional properties to the Fcγ receptor for IgG (FcγR). FcγR interferes with the anti-HCMV IgG antibody's binding to the virus, thus giving survival advantage to HCMV against antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent complement-dependent cytotoxicity ([@B5]; [@B76]).

A major issue in genetic epidemiology studies of antibody variation is that most of the genetic variation is ethnic and population specific. For example, GM 3 is rare among people of African descent. Moreover, the genetic background influencing overall immune response will be different between races and populations. Therefore replication and translation of results from one study to another is not always possible. Ethnic and population-specific genetic variation can also lead to hidden population stratification even in the same country, which is major factor confounding the genetic association results. Given the complex genetic nature of humoral immune response to HCMV, much larger studies with more balanced case and control groups are needed to test the GM associations with HCMV response.

Host Genetics of HCMV in Cancers {#s3}
================================

HCMV is not considered an oncogenic virus; however, HCMV viral DNA, RNA, and protein have been frequently found in neoplastic tissues including gliomas, breast cancer, and neuroblastoma ([@B16]; [@B39]; [@B15]; [@B113]; [@B121]). Moreover, HCMV infection leads to changes in cell physiology, tumor microenvironment, inhibition of apoptosis, and evasion from immune detection that are characteristics of cancer development ([@B38]). Not all HCMV-infected individuals develop cancers, suggesting that host genetics of HCMV response may influence HCMV-mediated cancer risk. Indeed, studies with glioma patient cohorts showed a modulating effect of GM alleles on the risk of gliomas, where the IgGM 3 homozygotes were over twice, and the GM 3/17 heterozygotes were over three times as likely to develop glioma ([@B78]; [@B79]). The magnitude of antibody responsiveness to HCMV glycoprotein B (gB) has also been implicated in breast cancer susceptibility. The GM 3 allele of IgG1 was reported to be significantly associated with increased susceptibility to breast cancer in Caucasian subjects from Brazil; however, the association was not significant in other population groups ([@B77]). In a follow-up study, breast cancer-free individuals had significantly higher levels of anti-gB IgG antibodies than patients with breast cancer; however, there was interindividual and interethnic variability in the magnitude of antibody response, and interactions with other genes of the immune system were apparent ([@B81]). Functional studies indicate that the binding of HCMV FcgR-like protein to GM 17 allele expressing IgG antibodies was significantly higher than GM 3 expressing antibodies, providing possible mechanistic insights for increased breast cancer risk in some HCMV-infected patients ([@B82]).

Significant association of rare GM genotypes with neuroblastoma, a rare extracranial solid tumor, has been reported ([@B71]), but the mechanism underlying this association is still not clear. These uncommon GM genotypes include the GM 3, the allele with high affinity to HCMV TRL11/IRL11-encoded FcγR. Reports documenting early and late HCMV protein expression in primary neuroblastomas and neuroblastoma xenografts suggest either infection and transformation of neuroblastoma progenitor cells or direct infection of neuroblastoma cells and disturbance of intracellular pathways leading to neoplasms ([@B121]). The mechanisms underlying the increased HCMV associated cancer risk with the GM 3 allele may also be involved in neuroblastoma cases as well.

Independent cohort and functional studies make a case for significant influence of host genetic variation in humoral immunity on response to HCMV disease ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}). However, increased cancer risk associated with increased HCMV susceptibility is still a hypothesis to be tested. Clearly, larger multi-ethnic, multi-cohort host genetic, and comprehensive functional studies are needed to uncover the host genetics of humoral immunity to HCMV and HCMV associated cancers.

Host Genetics of HCMV Disease in Transplant Patients {#s4}
====================================================

HCMV is a common opportunistic infection among immunocompromised individuals. Individuals are maximally immunocompromised due to use of immunosuppressants during solid organ or HSCT procedures and thus are prone to HCMV reactivation (of the latent virus), primary infection, and reinfection. HCMV infections can cause severe morbidity and transplant failure, which frequently results in extended hospital stay and substantially higher cost of care ([@B29]; [@B54]; [@B62]; [@B92]). Transplantations from a seropositive individual to a seronegative individual (R-/D+) pose the greatest risk for HCMV-associated disease in the transplant recipient patients ([@B17]; [@B64]). Therefore, determining the serologic status of the recipient and donor is important in assessing the risk of HCMV-associated disease. However, it can be hard to find serostatus matched donor and recipients, and even serostatus matching does not completely eliminate HCMV-associated morbidity.

Coordinated innate and adaptive immune response is crucial for control of HCMV infection in immunocompromised transplant recipients. Whereas innate interferon (IFN) and natural killer (NK) cell responses are important in immediate control of CMV infection, adaptive T cell immune responses are important in both active infection and reactivation control phases ([@B20]; [@B129]; [@B94]; [@B72]). To reduce the number of HCMV-associated adverse outcomes and better identify transplant patients for HCMV prophylaxis, several candidate innate and adaptive immune-related gene studies have been conducted ([**Table 1**](#T1){ref-type="table"}).

Solid Transplantation Studies {#s4_1}
-----------------------------

A family of transmembrane proteins, the Toll-like receptors (TLRs), are part of the innate immune system and play crucial roles in the activation of the immune system by regulating the production of antiviral peptides and inflammatory cytokines against viral replication. The detection of CMV envelope glycoproteins B (gB) and H (gH) by TLR2 leads to nuclear factor-kB (NF-kB) activation and cytokine secretion against CMV ([@B9]). Clinical studies showed that polymorphisms in TLR-2 ([@B52]; [@B49]), TLR-4, TLR-9 ([@B30]), and mannose binding lectin ([@B14]; [@B66]) can be associated with increased risk of HCMV infection and disease after transplantation.

Genetic variants of MICA (major histocompatibility complex class I chain-related protein A) and its activating receptor NKG2D (natural killer group 2 member D) receptor may be associated with HCMV disease risk among kidney transplant patients. A candidate gene association study identified a regulatory MICA variant (rs2596538) in the kidney donors that can be a protective prognostic determinant for CMV disease. This functional variant was able to predict the development of CMV infection and disease during the first year after kidney transplantation ([**Table 1**](#T1){ref-type="table"}: [@B95]). Membrane-associated molecule PD-1 (programmed death-1) regulates immune responses by inhibiting T cell receptor signaling, cytokine production in effector T cells, and expression on regulatory T cells ([@B105]; [@B33]). PD-1's expression also correlates with CMV viremia in transplant patients ([@B101]). An upstream regulatory region variant (rs11568821) that impairs the function of PD-1 (also called PD-1.3) has been investigated in HCMV infection in kidney and lung graft recipients. The PD-1.3 variant has been shown to be associated with higher risk of HCMV infection ([@B45]) and lung allograft survival in recipients from HCMV-positive donors ([@B32]). Dendritic cell-specific ICAM 3-grabbing nonintegrin (DC-SIGN) variants were also reported to be associated with higher incidence of HCMV infection in kidney transplant patients ([@B30]).

Cytokines, signaling molecules of the immune system, regulate pro-inflammatory and anti-inflammatory responses, and play important roles in antiviral response. Cytokines also play a role in HCMV infection, reactivation, and disease ([@B4]; [@B128]; [@B28]; [@B115]; [@B8]; [@B75]). Studies of functional gene polymorphisms in pro-inflammatory and anti-inflammatory cytokines with HCMV disease identified IFNG (interferon-gamma) +874 A/T polymorphism as a risk factor for HCMV disease in kidney and lung transplant patients, where the +874 A allele, a low IFNG producer (reduced gene expression), is associated with increased risk for HCMV infection and disease after organ transplantation ([@B70]; [@B117]). In a Finnish renal transplant cohort, the donor interleukin-10 (IL-10) gene polymorphism −1082AA was observed to influence HCMV infection risk. Recipient IL-10, IL-6, and IFNG polymorphisms also show significant associations with HCMV reactivation and disease risk ([@B1]). A possible association between IL-12p40 gene polymorphisms in the recipient and high risk of HCMV infection was also reported after kidney transplantation ([@B44]).

Type III interferon, also called interferon lambda (INFL3 or formerly IL-28B), has gained much attention as an important viral response element in recent years ([@B57]; [@B40]). In a cohort of solid organ transplant patients from Alberta, a functional single nucleotide polymorphism (SNP) (rs8099917) associated with lower INFL3 (IL-28B) expression during CMV infection, but higher IFN-stimulated gene expression showed a protective effect against CMV replication ([@B26]). A follow-up Swiss Transplant Cohort study compared the cumulative incidence of CMV replication between patients with different TT/-G (rs368234815) genotype in the CpG region upstream of IFNL3. Patients with the --G/--G genotype had higher cumulative incidence of CMV replication. The study suggest that IFNL3 TT/-G (rs368234815) variant can be a CMV replication controller, particularly in patients not receiving antiviral prophylaxis ([@B67]). [@B30] reported a lower incidence of HCMV infections among kidney transplant patients with IL28B (IFNL3) rs12979860-T allele.

Hematopoietic Transplantation Studies {#s4_2}
-------------------------------------

Although still few in number, host genetics of HCMV susceptibility among HSCT cases have also been investigated ([**Table 1**](#T1){ref-type="table"}). Similar to solid organ transplant studies, several candidate innate and adaptive immunity genes have been examined. Results from solid organ transplantation studies stimulated cytokine and interferon research in HCMV disease in stem cell transplant settings. In a comprehensive immunogenetic study, allogeneic stem cell transplant patients with HCMV reactivation (DNAemia), patients with HCMV disease, and patients without HCMV reactivation were examined ([@B63]). Polymorphisms in the CCR5, IL-10, and MCP1 were observed to contribute to HCMV reactivation and disease after allogeneic stem cell transplantation ([@B63]; [@B18]). In a follow-up study, this research group extended their investigation and observed a significant association between promoter region variants, which influenced the expression levels of DC-SIGN on dendritic cells, and increased risk of development of HCMV reactivation and disease ([@B69]). Protective effects of the INFL3 rs12979860 C/T polymorphism against CMV infection ([@B12]; [@B19]) and INFL3 rs12979860 IFNL4 rs368234815 compound genotype against HCMV reactivation ([@B2]) in the allogeneic stem cell transplant setting were also reported. Killer immunoglobulin-like receptors (KIR) are cell surface receptors found on NK and certain T cells. The activating and inhibitory signals are transmitted to NK cells through KIR proteins, by which NK cells respond quickly to infections. In a Chinese cohort HLA-matched HSCT patients, patients receiving HSCT from donors with heterozygote 2DS4+/1D+ KIR haplotype showed at least 20% less CMV reactivation compared to donors with other haplotypes ([@B122]). This observation suggests that donor KIR haplotype should be evaluated for HLA-matched HSCT cases. More recently functional genetic variants in *FOXP3* ([@B87]), *STAT4* ([@B123]), and *IL-7*([@B51]) are reported to influence HCMV infection after HSCT in independent cohort studies.

Host genetics of HCMV disease in transplant patients provide hints towards promising genetic markers to predict CMV viremia ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}). However, these studies are complicated due to several factors, including donor and recipient serostatus, type and dose of immunosuppressive drugs used, and ethnicity of the patient cohort. These factors also lead to significant heterogeneity among the studies confounding the efficacy of a meta-analysis of the individual studies to reach a consensus on securely identified markers and causal variants. The transplant community is still far from developing well accepted genetic markers for personalized CMV approaches (such as decisions on prophylactic and preemptive therapies) to be used in the clinic.

Host Genetics of HCMV Disease in HIV-Infected Patients {#s5}
======================================================

Patients with HIV infection are another group of immunocompromised individuals that are at high risk for CMV disease. Before the use of ART (antiretroviral therapy), up to 40% of adults with AIDS developed CMV disease ([@B34]). Although the incidence of CMV infection has declined dramatically, new cases continue to occur ([@B102]). Among HIV-infected patients the risk of CMV disease is linked to CD4+ T-cell counts. The most common CMV disease among patients with uncontrolled HIV infection is CMV-Retinitis that may develop when CD4+ T-cell counts drop below 50--100 CD4+ cells/µl ([@B47]; [@B25]; [@B41]). While some patients with low CD4+ T-cell counts remain asymptomatic, others can progress to CMV disease rather quickly. Host genetic variants in genes involved in regulation of innate and adaptive immune responses may have a role in this differential susceptibility to CMV among HIV-infected patients as they have in other immunocompromised groups such as transplant patients.

A comprehensive candidate gene study on host genetics of CMV-Retinitis among HIV-infected patients was conducted in Longitudinal Studies of Ocular Complications of AIDS (LSOCA) cohort ([**Table 1**](#T1){ref-type="table"}). The study showed that human interleukin-10 receptor (IL-10R1) variants that potentially interfere with IL-10 binding and signal transduction can influence CMV-Retinitis occurrence in European Americans ([@B103]). The same study also suggested a possible role of IL-10 variants on CMV-Retinitis risk among African Americans ([@B103]). In a follow-up study of the same cohort, cytokine and cytokine receptor \[*CCR5* and stromal derived factor (*SDF-1*)\] genetic variants have been observed to influence retinitis progression ([@B104]). In a different cohort study, *TNF* polymorphisms were also linked to susceptibility to CMV retinitis in white patients, though with rather small sample size ([@B23]). In a large Swiss HIV Cohort Study, the effect of *IFNL3* TT/-G substitution, the variant that increased susceptibility to CMV replication in transplant patients ([@B67]), was also shown to be associated with higher risk of CMV retinitis ([@B7]).

Although subject to complex confounding factors and high false discovery rates, host candidate gene studies of immunocompromised groups cumulatively indicate possible effects of innate and adaptive immune gene variants on CMV disease ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}). More studies should be designed to replicate and validate these results.

Host Genetics of Vertical HCMV Transmission {#s6}
===========================================

Vertical transmission of HCMV from mother to fetus or newborn is common and plays an important role in maintaining infection in the population ([@B108]; [@B118]). Prenatal infection rates are highest in low income countries or low socioeconomic populations, where risk of maternal seropositivity is also high ([@B109]; [@B110]). Recurrent and primary HCMV infection during pregnancy can cause congenital infection of the newborn and may lead to severe clinical complications such as hearing defects, birth defects, and irreversible neurodevelopmental sequelae ([@B11]; [@B10]; [@B35]).

Host candidate genetic studies of congenital HCMV infection mainly have focused on innate immune system, such as TLRs and Mannan-binding lectins, and cytokine genes ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}). In children with congenital HCMV disease, the TLR2 1350 T \> C variant (rs3804100) was reported to be associated with the infection, although no relationship was established with the course of infection (HCMV disease) ([@B114]). [@B27] reported a protective effect of TLR2 rs1898830 --GG genotype against HCMV transmission to fetus. A follow-up study investigating the influence of Arg677Trp (rs121917864, 2029 C \> T) and Arg753Gln (rs5743708) variants in the TLR2, and Asp299Gly variant in the TLR4 on the risk of CMV infection in infants and adults found that heterozygosity for the TLR2 Arg677Trp was significantly associated with a lower risk of CMV infection in adults but not in infants. The same study also reported TLR4 Asp299Gly association with lower viremia in the adults ([@B46]). In a study of HCMV-infected fetuses and neonates, and controls, [@B124] reported TLR2 2258 G \> A SNP (rs5743708) to be associated with increased risk of congenital HCMV infection, but no effect of TLR2 1350 T \> C and 2029 C \> T variants on HCMV risk was observed. The same group in an independent study evaluated the role of TLR2, TLR4, and TLR9 variants in HCMV infection among pregnant women. Only the TLR9 2848 G \> A (rs352140) variant was reported to be associated with HCMV infection risk in pregnant women ([@B125]). Increased HCMV infection risk in infants with TLR9 -1486 T \> C and TLR9 2848 C \> T variants is also reported ([@B83]).

Another important player in the innate immune system is the Mannan-binding lectin (MBL), a pattern recognition molecule and a first line defense antimicrobial factor ([@B53]). Mutations in the promoter region and first exon of *MBL2* were reported to be associated with lower serum MBL concentrations ([@B65]). In a Polish study, MBL2 functional gene polymorphisms that influence serum MBL concentrations were examined in prenatal and perinatal CMV infections ([@B112]). However, no significant influence on susceptibility to prenatal or perinatal HCMV infections was observed ([@B112]).

HCMV infection during pregnancy can affect the cytokine profile within a HCMV-infected placenta and shift the cytokine expression toward a proinflammatory state with implications for adverse pregnancy outcomes ([@B37]; [@B100]). As host genetic variants in cytokine-related genes were shown to influence susceptibility to HCMV infection and disease in transplant patients and patients with AIDS, several congenital infection studies also investigated the association of cytokine and cytokine receptor variants on HCMV susceptibility. [@B50] compared the allelic distribution of 11 candidate SNPs in eight genes (TNF rs1799964 and rs1800629, TNFRSF1A rs4149570, IL-1B rs16944 and rs1143634, IL-10 rs1800896, IL-10RA rs4252279, IL-12B rs3212227, CCL2 rs1024611 and rs13900, CCR5 rs333) between a group of infants (n = 72) with confirmed intrauterine CMV infection and 398 uninfected controls. IL-1B (rs16944) and TNF (rs1799964) variants were significantly associated with intrauterine HCMV infection. Moreover, they identified CCL2 (rs13900) as a genetic risk factor for hearing loss at birth and at 6 months of age ([@B50]). Wujcicka et al. examined the effects of fetal and maternal IL-1A, IL-1B, IL-6, IL-12B, and TNFA gene variants on HCMV infection and disease in neonates and fetuses in two independent Polish cohort studies. In one study, they reported that IL-1A and IL-1B variants increased the risk of congenital HCMV infection in neonates and fetuses, as well as the onset of disease-related symptoms ([@B126]). The other study of pregnant women also reported possible effects of IL-1A, IL-1B, and IL-6 on the occurrence and development of HCMV infection in the neonate ([@B127]).

Deciphering the contribution of hot genetics to HCMV vertical transmission and related disease outcomes may be the hardest of all HCMV-related disease studies. Firstly, the susceptibility of the pregnant mother to HCMV needs to be considered, where the immune response will be modified due to pregnancy further complicating the interaction between the host and HCMV. Secondly, if the mother cannot clear the infection, and HCMV finds its way to fetus, then the immune response by the infant, which is rather immature and still developing, will be involved with a genetic make-up different than that of the mother. Aforementioned reports should be considered as early attempts of a rather challenging research agenda. High-throughput genetic and immune profiling methods with much larger cohorts are necessary to understand the genetic and non-genetic factors involved in HCMV vertical transmission.

GWAS of HCMV Infection {#s7}
======================

Genome-wide association studies (GWASs) have made significant contributions for discovering genetic factors underlying complex phenotypes and diseases. Unlike traditional hypothesis-driven candidate gene studies, where only a few candidate genes are targeted, in GWAS all human genes become potential candidates for the phenotype of interest. Therefore, GWAS approach can discover genes and their variants that may look irrelevant to the phenotype of interest, which in return can lead to discovery of novel biological pathways involved in development of this phenotype.

The first GWAS was conducted to identify genetic polymorphisms associated with the susceptibility to HCMV and strength of anti-HCMV immunoglobulin G (IgG) response to CMV infection ([@B59]). The study included 1486 anti-CMV IgG seropositive and 648 seronegative individuals genotyped on an Illumina BeadChip containing 670,000 probes. Although no strong genetic components were observed, the study identified 10 new candidate loci that showed suggestive association with anti-CMV IgG titer ([**Table 1**](#T1){ref-type="table"}). Annotated genes among these loci suggested a possible role for microtubule network in anti-CMV antibody response ([@B59]). Another GWAS, aiming to localize the loci influencing serological phenotypes to common viral infections, found suggestive evidence of association for modifying IgG antibody response to HCMV (anti-CMV) on chromosome 14 ([@B96]). A retinol metabolism gene, *DHRS4*, near the associated SNP, was proposed to be a candidate for further evaluation. These two studies show that GWAS approach can be productive in HCMV field; however, one also needs to consider the fact that there was no overlap of identified genes between the two GWASs, although the phenotypes were similar. Curiously, none of the candidate innate and adaptive immune genes examined so far were top hits in these GWASs.

Challenge and Future Directions {#s7_1}
-------------------------------

Clinical management of CMV infection is particularly challenging due to the arsenal of host immune evasion strategies encoded by its large genome and its complex interactions with its human host. As we show in this review, with a few exceptions, most of the genetic loci identified to date have not been replicated or validated in sufficiently powered cohort studies, suggesting that only a small fraction of variance in host response is likely due to genetic variation. To address the role of host genetic variation in immune response to HCMV and CMV disease, large prospective studies and genome-wide approaches are required to securely identify causal variants involved in immune response and pathophysiological mechanisms leading to CMV disease.

Author Contributions {#s8}
====================

ES designed the study, conducted literature research, and wrote and edited the manuscript. PA and CW wrote and edited the manuscript.

Funding {#s9}
=======

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of Interest Statement {#s10}
==============================

PA and CW are employees of Leidos Biomedical Research, Inc., and declare no competing interest.

The remaining authors declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Dana C. Crawford, Case Western Reserve University, United States

[^2]: Reviewed by: Rui Medeiros, Portuguese Oncology Institute, Portugal; Michael G. Brown, University of Virginia, United States; David Navarro, Clinical University Hospital Valencia, Spain

[^3]: This article was submitted to Applied Genetic Epidemiology, a section of the journal Frontiers in Genetics
